Determining respiratory impairment in connective tissue disease-associated interstitial lung disease

Rheumatic Disease Clinics of North America

Volumn 41, Issue 2, 2015, Pages 213-223

  Assayag, Deborah ^a   Ryerson, Christopher J ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Connective tissue disease; Diagnosis; Interstitial lung disease; Pulmonary function testing; Respiratory impairment

Indexed keywords

BRONCHOSCOPY; CARDIOPULMONARY EXERCISE TEST; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; FUNCTIONAL ASSESSMENT; HIGH RESOLUTION COMPUTED TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG FUNCTION TEST; MIXED CONNECTIVE TISSUE DISEASE; MYOSITIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIX MINUTE WALK DISTANCE; SJOEGREN SYNDROME; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; COMPLICATION; CONNECTIVE TISSUE DISEASES; LUNG DISEASES, INTERSTITIAL; PATHOPHYSIOLOGY; RESPIRATORY TRACT EXAMINATION;

CONNECTIVE TISSUE DISEASES; DIAGNOSTIC TECHNIQUES, RESPIRATORY SYSTEM; HUMANS; LUNG DISEASES, INTERSTITIAL;

EID: 84926218673     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.12.003     Document Type: Review

References (43)

1. Swigris J.J., Yorke J., Sprunger D.B., et al. Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respir Med 2010, 104:1350-1355.
2. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
3. Cottin V., Thivolet-Bejui F., Reynaud-Gaubert M., et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003, 22:245-250.
4. Palm O., Garen T., Berge Enger T., et al. Clinical pulmonary involvement in primary Sjogren's syndrome: prevalence, quality of life and mortality: a retrospective study based on registry data. Rheumatology (Oxford) 2013, 52:173-179.
5. Parshall M.B., Schwartzstein R.M., Adams L., et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012, 185:435-452.
6. Papiris S.A., Daniil Z.D., Malagari K., et al. The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med 2005, 99:755-761.
7. Kozu R., Jenkins S., Senjyu H. Evaluation of activity limitation in patients with idiopathic pulmonary fibrosis grouped according to medical research council dyspnea grade. Arch Phys Med Rehabil 2014, 95:950-955.
8. Holland A.E., Fiore J.F., Bell E.C., et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology 2014, 9:1215-1221.
9. Pan L., Liu Y., Sun R., et al. Comparison of characteristics of connective tissue disease-associated interstitial lung diseases, undifferentiated connective tissue disease-associated interstitial lung diseases, and idiopathic pulmonary fibrosis in Chinese Han population: a retrospective study. Clin Dev Immunol 2013, 2013:121578.
10. Gochuico Br, Avila N.A., Chow C.K., et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008, 168:159-166.
11. Cordier J.F., Cottin V. Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis. Eur Respir J 2013, 42:916-923.
12. Rajasekaran A., Shovlin D., Saravanan V., et al. Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years. JRheumatol 2006, 33:1250-1253.
13. Ishioka S., Nakamura K., Maeda A., et al. Clinical evaluation of idiopathic interstitial pneumonia and interstitial pneumonia associated with collagen vascular disease using logistic regression analysis. Intern Med 2000, 39:213-219.
14. Nogueira C.R., Nápolis L.M., Bagatin E., et al. Lung diffusing capacity relates better to short-term progression on HRCT abnormalities than spirometry in mild asbestosis. Am J Ind Med 2011, 54:185-193.
15. Pellegrino R., Viegi G., Brusasco V., et al. Interpretative strategies for lung function tests. Eur Respir J 2005, 26:948-968.
16. Raghu G., Collard H.R., Egan J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
17. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.
18. Deuschle K., Weinert K., Becker M.O., et al. Six-minute walk distance as a marker for disability and complaints in patients with systemic sclerosis. Clin Exp Rheumatol 2011, 29:S53-S59.
19. Schoindre Y., Meune C., Dinh-Xuan A.T., et al. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. JRheumatol 2009, 36:1481-1485.
20. du Bois R.M., Albera C., Bradford W.Z., et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014, 43:1421-1429.
21. Ross R.M. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003, 167:211-277.
22. Dumitrescu D., Oudiz R.J., Karpouzas G., et al. Developing pulmonary vasculopathy in systemic sclerosis, detected with non-invasive cardiopulmonary exercise testing. PLoS One 2010, 5:e14293.
23. Armstrong H.F., Thirapatarapong W., Dussault N.E., et al. Distinguishing pulmonary hypertension in interstitial lung disease by ventilation and perfusion defects measured by cardiopulmonary exercise testing. Respiration 2013, 86:407-413.
24. Mathieson J.R., Mayo J.R., Staples C.A., et al. Chronic diffuse infiltrative lung disease: comparison of diagnostic accuracy of CT and chest radiography. Radiology 1989, 171:111-116.
25. van der Bruggen-Bogaarts B.A., Broerse J.J., Lammers J.W., et al. Radiation exposure in standard and high-resolution chest CT scans. Chest 1995, 107:113-115.
26. Assayag D., Elicker B.M., Urbania T.H., et al. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology 2014, 270:583-588.
27. Kim E.J., Elicker B.M., Maldonado F., et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010, 35:1322-1328.
28. Kocheril S.V., Appleton B.E., Somers E.C., et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Care Res 2005, 53:549-557.
29. Walsh S.L., Sverzellati N., Devaraj A., et al. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax 2014, 69:216-222.
30. Goh N.S., Desai S.R., Veeraraghavan S., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177:1248-1254.
31. Kowal-Bielecka O., Kowal K., Chyczewska E. Utility of bronchoalveolar lavage in evaluation of patients with connective tissue diseases. Clin Chest Med 2010, 31:423-431.
32. Urisman A., Jones K.D. Pulmonary pathology in connective tissue disease. Semin Respir Crit Care Med 2014, 35:201-212.
33. Winstone T.A., Assayag D., Wilcox P.G., et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014, 146:422-436.
34. Assayag D., Lubin M., Lee J.S., et al. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology 2014, 19:493-500.
35. Ryerson C.J., Vittinghoff E., Ley B., et al. Predicting survival across chronic interstitial lung disease: the ILD-gap model. Chest 2014, 145:723-728.
36. Chen J., Shi Y., Wang X., et al. Asymptomatic preclinical rheumatoid arthritis-associated interstitial lung disease. Clin Dev Immunol 2013, 2013:406927.
37. Kelly C.A., Saravanan V., Nisar M., et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics. A large multicentre UK study. Rheumatology (Oxford) 2014, 53:1676-1682.
38. Cepeda E.J., Reveille J.D. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 2004, 16:723-732.
39. Arai S., Kurasawa K., Maezawa R., et al. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis. Mod Rheumatol 2013, 23:872-883.
40. Tiev K.P., Hua-Huy T., Kettaneh A., et al. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir J 2011, 38:1355-1360.
41. Elhaj M., Charles J., Pedroza C., et al. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?. JRheumatol 2013, 40:1114-1120.
42. Tsuchiya Y., Takayanagi N., Sugiura H., et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 2011, 37:1411-1417.
43. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G., Anstrom K.J., et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. NEngl J Med 2012, 366:1968-1977.